Journal of travel medicine
-
Taiwan’s dengue cases vary annually, peaking in infrequent epidemics, which differ substantially from the Global Burden of Disease Study’s (GBD’s) projections. Although the GBD study provides invaluable insights into global health trends, its modelling approach fails to capture the dynamic change of dengue transmission.
-
Randomized Controlled Trial
A randomized, double-blinded phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults.
The global spread of the chikungunya virus (CHIKV) increases the exposure risk for individuals travelling to or living in endemic areas. This Phase 3 study was designed to demonstrate manufacturing consistency between three lots of the single shot live-attenuated CHIKV vaccine VLA1553, and to confirm the promising immunogenicity and safety data obtained in previous trials. ⋯ All three lots of VLA1553 recapitulated the safety and immunogenicity profiles of a preceding Phase 3 study, fulfilling pre-defined consistency requirements. These results highlight the manufacturability of VLA1553, a promising vaccine for the prevention of CHIKV disease for those living in or travelling to endemic areas.